On January 14, 2020, Gambacorti-Passerini, Carlo; Coutre, Philipp le; Piazza, Rocco published an article.SDS of cas: 380843-75-4 The title of the article was The role of bosutinib in the treatment of chronic myeloid leukemia. And the article contained the following:
A review. The availability of several BCR-ABL1 tyrosine kinase inhibitor (TKI) options means physicians and patients can select the most appropriate treatment for a patient with chronic myeloid leukemia (CML). BCR-ABL TKI selection as a first- or later-line therapy is dependent on a number of clin. factors. Regular monitoring of patients, patient education, dose optimization and management of treatment-emergent adverse events are key aspects of long-term chronic myeloid leukemia management and contribute to improved clin. outcomes, quality of life, patient adherence and healthcare costs. This review provides an overview of the BCR-ABL1 TKI bosutinib, its pharmacol. and clin. trials; discusses the impact of comorbidities and concomitant medications on bosutinib treatment selection; and suggests strategies for managing adverse events and dose optimization during bosutinib treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4
The Article related to review tyrosine kinase inhibitor bosutinib chronic myeloid leukemia pharmacol, bosutinib, chronic myeloid leukemia, first-line, later-line, treatment selection, Pharmacology: Reviews and other aspects.SDS of cas: 380843-75-4
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics